Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SAL0140 in primary aldosteronism
CTR20262073Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0140 in primary aldosteronism (PA), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started May 2026; status: active.
02
Drugs
SAL0140
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on CTR20262073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262073.